Key points are not available for this paper at this time.
The programme was terminated after phase IIa ended because efficacy was lower than with current nAMD treatments. According to elaborate post hoc analyses, the most likely reason was insufficient exposure in the target compartment (back of the eye).
Joussen et al. (Sat,) studied this question.